Name	Jeong-Ok Lee
Current Position & Affiliation	Professor, Seoul National University Bundang Hospital
Country	South Korea
Major Field	Lymphoma, CML

Educational Background

M.D. Yeungnam University College of Medicine, Daegu, Korea
M.Sc. Molecular oncology, Department of Medicine
Graduate School, Seoul National University College of Medicine, Seoul, Korea
Ph.D. Molecular oncology, Department of Medicine
Graduate School, Seoul National University College of Medicine, Seoul, Korea

Professional Experience

- Internship course, Seoul National University Hospital (SNUH), Seoul, Korea (2004)
- Resident course in Department of Internal Medicine, SNUH, Seoul, Korea (2005)
- Fellowship course in the Division of Hemato-oncology, SNUH, Seoul, Korea (2009)
- Instructor in Division of Hematology and Medical Oncology, Seoul National University Bundang Hospital (SNUBH), Seongnam-si, Korea (2010-)
- Assistant prof. in Division of Hematology and Medical Oncology, SNUBH, Seongnam-si, Korea (2012-)
- Associate prof. in Division of Hematology and Medical Oncology, SNUBH, Seongnam-si, Korea (2016-)
- Visiting Scholar, Leukemia service, Memorial Sloan Kettering Cancer Center, New York, NY, USA (2018)
- Prof. in Division of Hematology and Medical Oncology, SNUBH, Seongnam-si, Korea (2021-)

Other Experience and Professional Memberships

Member of the Korean Society of Hematology
Member of the Korean Society of Blood and Marrow Transplantation
Member of the Korean Society of Medical Oncology
Member of the American Society of Hematology

Main Scientific Publications

Lee JO, Park J, Kang HJ, Hyun SY, Lee GW, Yhim HY, Kim HJ, Lee JS, Heo DS, Kim TM. A Phase II Study of Bendamustine Plus Rituximab in Patients with Relapsed or Progressive Marginal Zone Lymphoma: KCSG LY14-09. 2025 Dec 3, online ahead of print

Lee JY, Kwon JH, Hur JY, Yi JH, Lee JH, Cho H, Do YR, Jo JC, Kang HJ, Koh Y, Lee WS, Lim SN, Yoon SE, Kim SJ, Lee JO. Pembrolizumab for Patients with Relapsed or Refractory Extranodal NK/T-Cell Lymphoma in Korea. Cancer Res Treat. 2024;56:681

Park C, Lee HS, Kang KW, Lee WS, Do YR, Kwak JY, Shin HJ, Kim SY, Yi JH, Lim SN, Lee JO, Yang DH, Jang H, Choi B, Lim J, Sun CH, Byun JM, Yoon SS, Koh Y. Combination of acalabrutinib with lenalidomide and rituximab in relapsed/ refractory aggressive B-cell non-Hodgkin lymphoma: a single-arm phase II trial. Nat commu. 2024;15:2776

Handa S, Lee JO, Derkach A, Stone RM, Saven A, Altman JK, Grever MR, Rai KR, Shukla M, Vemuri S, Montoya S, Taylor J, Abdel-Wahab O, Tallman MS, Park JH. Long-term outcomes in patients with relapsed or refractory hairy cell leukemia treated with vemurafenib monotherapy. Blood. 2022;140:2663-2671

Nawas MT, Lee JO, Flynn J, Maloy M, Jakubowski AA, Papadopoulos EB, Cho C, Ponce DM, Sauter CS, Perales MA, Devlin S, Giralt SA, Castro-Malaspina HR, Tamari R. CD34+ -selected hematopoietic stem cell transplant conditioned with a myeloablative regimen in patients with advanced myelofibrosis.
Bone Marrow Transplant. 2022;57:1101-1107
Kim SA, Kwon BS, Chung JH, Lee JY, Bang SM, Lee JO. Interstitial pneumonitis associated with dasatinib treatment for chronic myeloid leukemia or acute lymphoblastic leukemia: case series and a literature review. Ther Adv Respir Dis. 2022 Jan-Dec;16:17534666221135322.
Lee JY, Paik JH, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Lee KW, Kim JH, Bang SM, Lee JS, Lee JO. R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience. Blood Res 2021;56:285-292
Byun JM, Shin DY, Koh Y, Hong J, Kim I, Yoon SS, Lee JY, Bang SM, Lee JO. Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia in first complete remission? Ther Adv Hematol 2021 Apr 20
Lee JY, Kang M, Suh KJ, Kim JW, Kim SH, Kim JW, Kim YJ, Song KH, Kim ES, Kim HB, Lee KW, Kim JH, Bang SM, Lee JS, Lee JO. Pneumocystis jirovecii pneumonia in Diffuse Large B-Cell Lymphoma Treated with R-CHOP. Mycoses 2021;64:60-65